Lloyd Howard Kasper
Physician in Norwich, VT
License number
Colorado 33213
Issued Date
Dec 17, 1993
Renew Date
Jun 1, 2009
Expiration Date
May 31, 2011
Type
Physician
Address
Address
Box 1022, Norwich, VT 05055
Professional information
Method Of Augmenting T Cell-Mediated Immunity Against Toxoplasma Gondii
US Patent:
6399077, Jun 4, 2002
Filed:
May 19, 1999
Appl. No.:
09/230914
Inventors:
Lloyd H. Kasper - Norwich VT
Imtiaz A. Khan - Hanover NH
Imtiaz A. Khan - Hanover NH
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 39012
US Classification:
4242731, 424 851, 424 852, 4242651
Abstract:
A method of augmenting T cell-mediated immunity against is provided. Immunization with soluble parasite antigen and exogenous rIL-15 was found to protect against infection.
Cytokine Biomarkers As Predictive Biomarkers Of Clinical Response For Glatiramer Acetate
US Patent:
2012012, May 17, 2012
Filed:
Oct 10, 2011
Appl. No.:
13/269913
Inventors:
Lloyd H. Kasper - Norwich VT, US
Jacqueline Y. Smith - Lebanon NH, US
Jacqueline Y. Smith - Lebanon NH, US
International Classification:
A61K 38/16, A61P 25/00, A61P 37/06, C40B 30/00
US Classification:
4241841, 506 7
Abstract:
A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-α concentration, IL-2 concentration and IFN-γ concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.
Nutraceutical Composition And Methods For Preventing Or Treating Multiple Sclerosis
US Patent:
2011000, Jan 13, 2011
Filed:
Jul 20, 2010
Appl. No.:
12/839577
Inventors:
Lloyd H. Kasper - Norwich VT, US
International Classification:
A61K 31/715, A61P 25/00, C12N 5/0783
US Classification:
514 54, 435375
Abstract:
The present invention embraces nutraceutical compositions containing isolated capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
Nutraceutical Composition And Methods For Preventing Or Treating Multiple Sclerosis
US Patent:
8580278, Nov 12, 2013
Filed:
Jun 17, 2011
Appl. No.:
13/162644
Inventors:
Lloyd H. Kasper - Norwich VT, US
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 39/02, A61K 31/715, A01N 43/04
US Classification:
4242341, 514 54
Abstract:
The present invention embraces nutraceutical compositions containing isolated capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
P30 Peptides Of Toxoplasma Gondii
US Patent:
5859196, Jan 12, 1999
Filed:
Jun 5, 1995
Appl. No.:
8/461296
Inventors:
John Charles Boothroyd - Palo Alto CA
James Lawrence Burg - Foster City CA
Lloyd H. Kasper - Norwich VT
James Lawrence Burg - Foster City CA
Lloyd H. Kasper - Norwich VT
Assignee:
Trustees of the Leland Stanford Junior University - Hanover NH
Trustees of Dartmouth College - Stanford CA
Trustees of Dartmouth College - Stanford CA
International Classification:
C12N 1563, C12N 510
US Classification:
530350
Abstract:
Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.
Prevention Or Treatment Of Immune-Relevant Disease By Modification Of Microfloral Populations
US Patent:
8586029, Nov 19, 2013
Filed:
Jun 3, 2009
Appl. No.:
12/993909
Inventors:
Lloyd H. Kasper - Norwich VT, US
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A01N 63/00
US Classification:
424 9371
Abstract:
The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.
Nutraceutical Composition And Methods For Preventing Or Treating Multiple Sclerosis
US Patent:
2010031, Dec 9, 2010
Filed:
Nov 3, 2009
Appl. No.:
12/611627
Inventors:
Lloyd H. Kasper - Norwich VT, US
International Classification:
A61K 31/715, A61P 37/00
US Classification:
514 54
Abstract:
The present invention embraces nutraceutical compositions containing isolated capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.
Method For Stimulating Foxp3+ Regulatory T Cell Expression Of Cd39
US Patent:
2014003, Jan 30, 2014
Filed:
Jul 19, 2011
Appl. No.:
13/811002
Inventors:
Lloyd H. Kasper - Norwich VT, US
Assignee:
TRUSTEES OF DARTMOUTH COLLEGE - Hanover NH
International Classification:
C12N 5/0783
US Classification:
435375
Abstract:
Disclosed is the use of isolated capsular polysaccharide A in a method for stimulating FoxP3+ regulatory T cell expression of CD39.
Diagnostic Genes For Toxoplasmosis
US Patent:
5629414, May 13, 1997
Filed:
Jan 14, 1994
Appl. No.:
8/182673
Inventors:
John C. Boothroyd - Palo Alto CA
James L. Burg - Foster City CA
Lloyd H. Kasper - Norwich VT
James L. Burg - Foster City CA
Lloyd H. Kasper - Norwich VT
Assignee:
The Board of Trustees of the Leeland Stanford Junior University - Stanford CA
International Classification:
C07H 2100, C12N 120, C12N 1500
US Classification:
536 237
Abstract:
Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.